The anti-hepatocellular carcinoma activity of compounds 5a–i and doxorubicin against HepG2 and Huh7.
| Compound | IC50a (μM) | |
|---|---|---|
| HepG2 | Huh7 | |
| 5a | 11.20 ± 1.92 | 7.27 ± 0.39 |
| 5b | 3.57 ± 3.08 | 2.17 ± 0.83 |
| 5c | 4.94 ± 1.64 | 8.32 ± 0.29 |
| 5d | 22.55 ± 3.24 | 25.01 ± 3.11 |
| 5e | 2.58 ± 2.9 | 2.44 ± 0.81 |
| 5f | 8.14 ± 0.06 | 6.70 ± 0.73 |
| 5g | 5.08 ± 0.65 | 1.58 ± 1.15 |
| 5h | 1.95 ± 2.41 | 0.55 ± 0.52 |
| 5i | 31.14 ± 1.76 | 23.08 ± 1.1 |
| Doxorubicin | 7.34 ± 0.09 | 5.70 ± 0.21 |
| Stattic | 8.35 ± 0.30 | 7.89 ± 0.25 |
a
The IC50 values displayed here are the mean of three distinct studies ± S.D.